Sign Out
No interaction studies have been performed.
No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/mL) following ocular dosing with bimatoprost 0.03% eyedrops. Bimatoprost is biotransformed by any of multiple enzymes and pathways, and no effects on hepatic drug metabolizing enzymes were observed in preclinical studies in rats and monkeys.
In clinical studies, LUMIGAN 0.03% eye drops (multidose) was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Concomitant use of LUMIGAN and antiglaucomatous agents other than topical beta-blockers has not been evaluated during adjunctive glaucoma therapy.
There is a potential for the IOP-lowering effect of prostaglandin analogs (e.g., LUMIGAN) to be reduced in patients with glaucoma or ocular hypertension when used with other prostaglandin analogs.
Continue with Google